Amicus Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell FOLD and other ETFs, options, and stocks.About FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.
CEOBradley Lewis Campbell
CEOBradley Lewis Campbell
Employees499
Employees499
HeadquartersPrinceton, New Jersey
HeadquartersPrinceton, New Jersey
Founded2002
Founded2002
Employees499
Employees499
FOLD Key Statistics
Market cap1.88B
Market cap1.88B
Price-Earnings ratio-64.28
Price-Earnings ratio-64.28
Dividend yield—
Dividend yield—
Average volume6.16M
Average volume6.16M
High today$6.16
High today$6.16
Low today$5.97
Low today$5.97
Open price$6.01
Open price$6.01
Volume3.12M
Volume3.12M
52 Week high$12.65
52 Week high$12.65
52 Week low$5.51
52 Week low$5.51
FOLD News
TipRanks 2d
Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease TreatmentAmicus Therapeutics ((FOLD)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50...
Analyst ratings
82%
of 11 ratingsBuy
81.8%
Hold
18.2%
Sell
0%
People also own
Based on the portfolios of people who own FOLD. This list is generated using Robinhood data, and it’s not a recommendation.